Company news
Tissue Repair Ltd (ASX:TRP) news
Tissue Repair Ltd news releases on 6ix. Latest, Sep 2, 2026: TRP to resume direct distribution of TR Pro in ANZ
Press releases & updates
TRP to resume direct distribution of TR Pro in ANZ
September 1, 2026
Appendix 4E and Annual Report 30 June 2026
August 31, 2026
Voluntary Delisting
July 22, 2026
Appendix 4D and Half Year Report to 31 December 2025
February 27, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 30, 2026
Response to ASX Price Query
December 10, 2025
Pause in Trading
December 10, 2025
Appendix 4E and Annual Report 30 June 2025
August 29, 2025
Major Distribution Agreement secured for TR Pro
July 11, 2025
Appendix 4D and Half Year Report to 31 December 2024
February 27, 2025
Phase 3 Clinical Trial Programme for TR987
January 29, 2025
Takeover Panel Media release & Independent Director changes
September 25, 2024
Appendix 4E and Annual Report 30 June 2024
August 22, 2024
Tony Charara Co-founder appointed as CEO
August 8, 2024
TGA approval granted for Tissue Repair TR Pro
July 25, 2024
Appendix 4D and Half Year Report to 31 December 2023
February 28, 2024
Third US Patent granted for Tissue Repair Glucoprime
December 18, 2023
Appendix 4E and Annual Report 30 June 2023
August 30, 2023
FDA clears TR-987 to progress to Phase 3
May 28, 2023
Bank Deposits At SVB Available Tuesday 14 March 2023 AEDT
March 13, 2023
Update on Cash Held with Silicon Valley Bank
March 12, 2023
Appendix 4D and Half Year Report to 31 December 2022
February 22, 2023
TR Pro accepted for peer reviewed journal publication
October 12, 2022
FDA Response Clarifies Path to Phase 3 Trials
September 28, 2022
Second US Patent granted for Glucoprime
September 5, 2022
Appendix 4E and Annual Report 30 June 2022
August 31, 2022
Lodgement of Type C Meeting Request with US FDA
July 1, 2022
Tissue Repair Announces USA Patent Approval
March 3, 2022
Appendix 4D and Half Year Report to 31 December 2021
February 24, 2022
Tissue Repair Progresses TR-987 towards Phase III
November 22, 2021